Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis

Summary A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental immunology 2018-04, Vol.192 (1), p.7-17
Hauptverfasser: Kaplan, B., Golderman, S., Ganelin‐Cohen, E., Miniovitch, A., Korf, E., Ben‐Zvi, I., Livneh, A., Flechter, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 17
container_issue 1
container_start_page 7
container_title Clinical and experimental immunology
container_volume 192
creator Kaplan, B.
Golderman, S.
Ganelin‐Cohen, E.
Miniovitch, A.
Korf, E.
Ben‐Zvi, I.
Livneh, A.
Flechter, S.
description Summary A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. The FLC indices accounting for the total FLC levels and for the monomer/dimer ratios of κ and λ FLC were calculated, and the cut‐off values of the FLC indices were determined to distinguish healthy state from MS disease. The obtained FLC index values were statistically different in the saliva of three groups: active MS patients, MS patients in remission and healthy subjects groups. Our FLC monomer–dimer analysis allowed differentiation between healthy state and active MS with specificity of 100% and a sensitivity of 88·5%. The developed technique may serve as a new non‐invasive complementary tool to evaluate the disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%. A new procedure based on a semiquantitative Western blot analysis was developed to study saliva immunoglobulin free light chain (FLC) monomers (25 kDa) and dimers (50kDa) of κ and λ type. Striking differences were revealed by comparing saliva FLC monomer‐dimer patterns of active MS patients (a2, b2, c2, d2, e2) versus patients in remission (c1, d1, e1) or healthy subjects (a1 and b1): active MS patients showed abnormally elevated level of FLC monomers and/or of both monomeric and dimeric FLC. The developed technique may serve as a new non‐invasive complimentary tool to evaluate the MS disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%.
doi_str_mv 10.1111/cei.13086
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5842412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1971694594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-3e9d0d6945cb144ca7e59028cb3985b8ce7d38a9355f486cc67997e6456e55f43</originalsourceid><addsrcrecordid>eNp1kUFv3CAQhVHUKtmkPeQPVEi9NAcngAGbHCJVq7RdKVIvyRlhPN4lxWYD9lb774u7aZRWKpcRMx-PBw-hc0ouaV5XFtwlLUktj9CCllIUjHH1Bi0IIapQlPATdJrSY95KKdkxOmGKKi4UWyC36vtpCGsfmsm7AXcRAHu33ozYbowbEs7NZLzbmWts8DaMMIzOeNyb-AMi7kLErUtgEmBjR7dz434-0k9-dFsPOFkPMSSX3qG3nfEJ3j_XM_Tw5fZ--a24-_51tfx8V1jOS1mUoFrSymzPNpRzayoQirDaNqWqRVNbqNqyNqoUouO1tFZWSlUguZAwt8ozdHPQ3U5ND63NfqPxehtdtrzXwTj992RwG70OOy1qzjhlWeDTs0AMTxOkUfcuWfDeDBCmpKmq6OxPzXd9_Ad9DFMc8vM0I5QKyQmXmbo4UDZ_RIrQvZihRM8B6hyg_h1gZj-8dv9C_kksA1cH4KfzsP-_kl7erg6SvwDIPaYc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2011564046</pqid></control><display><type>article</type><title>Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kaplan, B. ; Golderman, S. ; Ganelin‐Cohen, E. ; Miniovitch, A. ; Korf, E. ; Ben‐Zvi, I. ; Livneh, A. ; Flechter, S.</creator><creatorcontrib>Kaplan, B. ; Golderman, S. ; Ganelin‐Cohen, E. ; Miniovitch, A. ; Korf, E. ; Ben‐Zvi, I. ; Livneh, A. ; Flechter, S.</creatorcontrib><description>Summary A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. The FLC indices accounting for the total FLC levels and for the monomer/dimer ratios of κ and λ FLC were calculated, and the cut‐off values of the FLC indices were determined to distinguish healthy state from MS disease. The obtained FLC index values were statistically different in the saliva of three groups: active MS patients, MS patients in remission and healthy subjects groups. Our FLC monomer–dimer analysis allowed differentiation between healthy state and active MS with specificity of 100% and a sensitivity of 88·5%. The developed technique may serve as a new non‐invasive complementary tool to evaluate the disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%. A new procedure based on a semiquantitative Western blot analysis was developed to study saliva immunoglobulin free light chain (FLC) monomers (25 kDa) and dimers (50kDa) of κ and λ type. Striking differences were revealed by comparing saliva FLC monomer‐dimer patterns of active MS patients (a2, b2, c2, d2, e2) versus patients in remission (c1, d1, e1) or healthy subjects (a1 and b1): active MS patients showed abnormally elevated level of FLC monomers and/or of both monomeric and dimeric FLC. The developed technique may serve as a new non‐invasive complimentary tool to evaluate the MS disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1111/cei.13086</identifier><identifier>PMID: 29194592</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Biomarkers - analysis ; Blotting, Western - methods ; dimers ; Female ; Humans ; immunoglobulin free light chains ; Immunoglobulin kappa-Chains - analysis ; Immunoglobulin lambda-Chains - analysis ; Immunoglobulin Light Chains - analysis ; Immunoglobulins ; Light chains ; Male ; Middle Aged ; monomers ; Multiple sclerosis ; Multiple Sclerosis - diagnosis ; Original ; Remission ; Saliva ; Saliva - chemistry ; Sensitivity ; Sensitivity and Specificity</subject><ispartof>Clinical and experimental immunology, 2018-04, Vol.192 (1), p.7-17</ispartof><rights>2017 British Society for Immunology</rights><rights>2017 British Society for Immunology.</rights><rights>2018 British Society for Immunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-3e9d0d6945cb144ca7e59028cb3985b8ce7d38a9355f486cc67997e6456e55f43</citedby><cites>FETCH-LOGICAL-c4436-3e9d0d6945cb144ca7e59028cb3985b8ce7d38a9355f486cc67997e6456e55f43</cites><orcidid>0000-0003-1486-681X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842412/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842412/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29194592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaplan, B.</creatorcontrib><creatorcontrib>Golderman, S.</creatorcontrib><creatorcontrib>Ganelin‐Cohen, E.</creatorcontrib><creatorcontrib>Miniovitch, A.</creatorcontrib><creatorcontrib>Korf, E.</creatorcontrib><creatorcontrib>Ben‐Zvi, I.</creatorcontrib><creatorcontrib>Livneh, A.</creatorcontrib><creatorcontrib>Flechter, S.</creatorcontrib><title>Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>Summary A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. The FLC indices accounting for the total FLC levels and for the monomer/dimer ratios of κ and λ FLC were calculated, and the cut‐off values of the FLC indices were determined to distinguish healthy state from MS disease. The obtained FLC index values were statistically different in the saliva of three groups: active MS patients, MS patients in remission and healthy subjects groups. Our FLC monomer–dimer analysis allowed differentiation between healthy state and active MS with specificity of 100% and a sensitivity of 88·5%. The developed technique may serve as a new non‐invasive complementary tool to evaluate the disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%. A new procedure based on a semiquantitative Western blot analysis was developed to study saliva immunoglobulin free light chain (FLC) monomers (25 kDa) and dimers (50kDa) of κ and λ type. Striking differences were revealed by comparing saliva FLC monomer‐dimer patterns of active MS patients (a2, b2, c2, d2, e2) versus patients in remission (c1, d1, e1) or healthy subjects (a1 and b1): active MS patients showed abnormally elevated level of FLC monomers and/or of both monomeric and dimeric FLC. The developed technique may serve as a new non‐invasive complimentary tool to evaluate the MS disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%.</description><subject>Adult</subject><subject>Biomarkers - analysis</subject><subject>Blotting, Western - methods</subject><subject>dimers</subject><subject>Female</subject><subject>Humans</subject><subject>immunoglobulin free light chains</subject><subject>Immunoglobulin kappa-Chains - analysis</subject><subject>Immunoglobulin lambda-Chains - analysis</subject><subject>Immunoglobulin Light Chains - analysis</subject><subject>Immunoglobulins</subject><subject>Light chains</subject><subject>Male</subject><subject>Middle Aged</subject><subject>monomers</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Original</subject><subject>Remission</subject><subject>Saliva</subject><subject>Saliva - chemistry</subject><subject>Sensitivity</subject><subject>Sensitivity and Specificity</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFv3CAQhVHUKtmkPeQPVEi9NAcngAGbHCJVq7RdKVIvyRlhPN4lxWYD9lb774u7aZRWKpcRMx-PBw-hc0ouaV5XFtwlLUktj9CCllIUjHH1Bi0IIapQlPATdJrSY95KKdkxOmGKKi4UWyC36vtpCGsfmsm7AXcRAHu33ozYbowbEs7NZLzbmWts8DaMMIzOeNyb-AMi7kLErUtgEmBjR7dz434-0k9-dFsPOFkPMSSX3qG3nfEJ3j_XM_Tw5fZ--a24-_51tfx8V1jOS1mUoFrSymzPNpRzayoQirDaNqWqRVNbqNqyNqoUouO1tFZWSlUguZAwt8ozdHPQ3U5ND63NfqPxehtdtrzXwTj992RwG70OOy1qzjhlWeDTs0AMTxOkUfcuWfDeDBCmpKmq6OxPzXd9_Ad9DFMc8vM0I5QKyQmXmbo4UDZ_RIrQvZihRM8B6hyg_h1gZj-8dv9C_kksA1cH4KfzsP-_kl7erg6SvwDIPaYc</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Kaplan, B.</creator><creator>Golderman, S.</creator><creator>Ganelin‐Cohen, E.</creator><creator>Miniovitch, A.</creator><creator>Korf, E.</creator><creator>Ben‐Zvi, I.</creator><creator>Livneh, A.</creator><creator>Flechter, S.</creator><general>Oxford University Press</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1486-681X</orcidid></search><sort><creationdate>201804</creationdate><title>Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis</title><author>Kaplan, B. ; Golderman, S. ; Ganelin‐Cohen, E. ; Miniovitch, A. ; Korf, E. ; Ben‐Zvi, I. ; Livneh, A. ; Flechter, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-3e9d0d6945cb144ca7e59028cb3985b8ce7d38a9355f486cc67997e6456e55f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Biomarkers - analysis</topic><topic>Blotting, Western - methods</topic><topic>dimers</topic><topic>Female</topic><topic>Humans</topic><topic>immunoglobulin free light chains</topic><topic>Immunoglobulin kappa-Chains - analysis</topic><topic>Immunoglobulin lambda-Chains - analysis</topic><topic>Immunoglobulin Light Chains - analysis</topic><topic>Immunoglobulins</topic><topic>Light chains</topic><topic>Male</topic><topic>Middle Aged</topic><topic>monomers</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Original</topic><topic>Remission</topic><topic>Saliva</topic><topic>Saliva - chemistry</topic><topic>Sensitivity</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaplan, B.</creatorcontrib><creatorcontrib>Golderman, S.</creatorcontrib><creatorcontrib>Ganelin‐Cohen, E.</creatorcontrib><creatorcontrib>Miniovitch, A.</creatorcontrib><creatorcontrib>Korf, E.</creatorcontrib><creatorcontrib>Ben‐Zvi, I.</creatorcontrib><creatorcontrib>Livneh, A.</creatorcontrib><creatorcontrib>Flechter, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaplan, B.</au><au>Golderman, S.</au><au>Ganelin‐Cohen, E.</au><au>Miniovitch, A.</au><au>Korf, E.</au><au>Ben‐Zvi, I.</au><au>Livneh, A.</au><au>Flechter, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2018-04</date><risdate>2018</risdate><volume>192</volume><issue>1</issue><spage>7</spage><epage>17</epage><pages>7-17</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><abstract>Summary A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. The FLC indices accounting for the total FLC levels and for the monomer/dimer ratios of κ and λ FLC were calculated, and the cut‐off values of the FLC indices were determined to distinguish healthy state from MS disease. The obtained FLC index values were statistically different in the saliva of three groups: active MS patients, MS patients in remission and healthy subjects groups. Our FLC monomer–dimer analysis allowed differentiation between healthy state and active MS with specificity of 100% and a sensitivity of 88·5%. The developed technique may serve as a new non‐invasive complementary tool to evaluate the disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%. A new procedure based on a semiquantitative Western blot analysis was developed to study saliva immunoglobulin free light chain (FLC) monomers (25 kDa) and dimers (50kDa) of κ and λ type. Striking differences were revealed by comparing saliva FLC monomer‐dimer patterns of active MS patients (a2, b2, c2, d2, e2) versus patients in remission (c1, d1, e1) or healthy subjects (a1 and b1): active MS patients showed abnormally elevated level of FLC monomers and/or of both monomeric and dimeric FLC. The developed technique may serve as a new non‐invasive complimentary tool to evaluate the MS disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>29194592</pmid><doi>10.1111/cei.13086</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1486-681X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9104
ispartof Clinical and experimental immunology, 2018-04, Vol.192 (1), p.7-17
issn 0009-9104
1365-2249
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5842412
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Adult
Biomarkers - analysis
Blotting, Western - methods
dimers
Female
Humans
immunoglobulin free light chains
Immunoglobulin kappa-Chains - analysis
Immunoglobulin lambda-Chains - analysis
Immunoglobulin Light Chains - analysis
Immunoglobulins
Light chains
Male
Middle Aged
monomers
Multiple sclerosis
Multiple Sclerosis - diagnosis
Original
Remission
Saliva
Saliva - chemistry
Sensitivity
Sensitivity and Specificity
title Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A24%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoglobulin%20free%20light%20chains%20in%20saliva:%20a%20potential%20marker%20for%20disease%20activity%20in%20multiple%20sclerosis&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=Kaplan,%20B.&rft.date=2018-04&rft.volume=192&rft.issue=1&rft.spage=7&rft.epage=17&rft.pages=7-17&rft.issn=0009-9104&rft.eissn=1365-2249&rft_id=info:doi/10.1111/cei.13086&rft_dat=%3Cproquest_pubme%3E1971694594%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2011564046&rft_id=info:pmid/29194592&rfr_iscdi=true